{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.4","upperLimit":"88.2","value":"66.7"}]}],"title":"10^-4 cutoff"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.4","upperLimit":"88.2","value":"66.7"}]}],"title":"10^-5 cutoff"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.6","upperLimit":"78.7","value":"53.3"}]}],"title":"10^-6 cutoff"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"MRD-negative rate is defined as the percentage of participants with negative MRD status (at 10\\^-4, 10\\^-5 and 10\\^-6 cutoffs) by bone marrow aspirate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants aged 18 years or older, with multiple myeloma received the lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion and fludarabine 30 mg/m\\^2 IV infusion daily, for 3 days \\[Day -7 to Day -5\\]). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants received IV infusion of cilta-cel OOS at a total targeted dose of 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg (dose range 0.5\\*10\\^6 CAR-positive viable T cells/kg to 1.0\\*10\\^6 CAR-positive viable T cells/kg) based on participant's body weight at apheresis or per exceptional release criteria determined alternative dose.","id":"OG000","title":"Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS)"}],"paramType":"NUMBER","populationDescription":"All participants who received cilta-cel OOS and had evaluable MRD samples in all treated analysis set. The all treated analysis set included all participants who received study intervention (cilta-cel OOS). Here, 'N' (number of participants analyzed) signifies number of participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From Day 1 (post infusion) up to 18.6 months","title":"Minimal Residual Disease (MRD)-Negative Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}